Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan maintains a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and raises the price target from $19 to $21.
February 29, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Buy rating on Iovance Biotherapeutics and increases the price target from $19 to $21.
The upgrade in the price target by a reputable analyst firm like Goldman Sachs typically signals a positive outlook on the stock, suggesting potential upside. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100